US20040170712A1 - Medical effect of Jojoba Oil in the treatment of skin diseases - Google Patents
Medical effect of Jojoba Oil in the treatment of skin diseases Download PDFInfo
- Publication number
- US20040170712A1 US20040170712A1 US10/792,632 US79263204A US2004170712A1 US 20040170712 A1 US20040170712 A1 US 20040170712A1 US 79263204 A US79263204 A US 79263204A US 2004170712 A1 US2004170712 A1 US 2004170712A1
- Authority
- US
- United States
- Prior art keywords
- oil
- jojoba oil
- jojoba
- treatment
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/004—Preparations used to protect coloured hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- the present invention relates to various medical effects of the Jojoba oil.
- Jojoba oil is used in Lubricating motors and added to some cosmetic preparations.
- Such previous uses of Jojoba Oil are not related to the new uses subjected to this invention.
- Jojoba Oil may be used in accordance with the treatment of and preventative measures associated with Gynecology of Obstetrics and general surgery, as well as in the treatment of eye diseases, inflammation of the internal, middle or external ear, rheumatic pain and arthritis, gingivostomatitis, toothache and dermal diseases.
- the Jojoba Oil is preferably extruded in accordance with the present invention.
- Natural Jojoba oil is extracted from seeds of Jojoba shrub ⁇ Simmondsia Chinensis (LINK) Schnieder ⁇ . It is made up of straight chain esters of mono-unsaturated long chain fatty acids and fatty alcohols and has an average total carbon chain length of 42 carbons, so it is classified chemically as a liquid wax.
- Jojoba oil is composed entirely of esters of high molecular weight, straight chain mono-ethylenic acids and mono-ethylenic alcohols.
- the unsaturated acids are mixture of eicosanoic (C20) and docosanoic (C22), with small quantities of palmiloleic (C18) and oleic (C16) acids.
- the unsaturated alcohols are a mixture of eicosanol and docosanol, with smaller quantities of hexacosanol and alcohols of lower molecular weight.
- Jojoba oil is non-volatile and free from rancidity, and this is attributed in part to presence of tocopherols (natural anti-oxidant) as a minor constituent and mainly to its wax structure (It has only one alcohol group, so it is not subject to oxidation and will never become rancid). Furthermore, researches showed that Jojoba oil possesses the six general factors which increase permeation into stratum cornium:—low viscosity, high unsaturation, low saponification number, short carbon chain length, low lecithin (Jojoba oil has no lecithin), straight chain molecule and branched esters.
- Jojoba oil helps to avoid the two important causes of premature aging of the skin:—dryness and lipid perioxidation. It serves as an excellent non-occlusive moisturizing agent that enhances the flexibility and suppleness of the skin. At the same time, its exceptional non-tacky spread and lubricity leave a rich velvety after-feel.
- Jojoba oil is characterized by having 50% of its content as Disponifiables (Triterpene alcohols and Phytosterols) while other vegetable oil contain only 2-3%. Moreover applying Emponifiables to skin increases elastin formation, which in turn increases skin luster, elasticity and integration. Jojoba Oil also provides skin protection as it has anti-allergic properties, disinfectant, and produces cell stimulation, skin regeneration and stops inflammation. The pH of Jojoba oil is balanced and reveals beneficial effects for dry and damaged skin.
- Emponifiables Triterpene alcohols and Phytosterols
- Jojoba oil is also proven to have anti-inflammatory and anti-microbial effects as well.
- Five of the most common bacteria including staphylococcus aureus and pseudomonas aeruginosa as well as fungus candida albicans are not able to grow in Jojoba oil.
- the Jojoba Oil from the Jojoba seeds contains 50-55% of its weight oil.
- the Jojoba oil is extracted in phase one by pressing the Jojoba seeds under pressure reaching gradually from 1 to 35-38 Ton/Inch.
- About 26-28% oil from the seeds weight is obtained form the first pressing phase, also called phase one oil, which may be used for medical application.
- the residual squeezed seeds are pressed again under pressure up to 100 Ton/Inch, which extracts second phase oil, which may be used in cosmetic and other fields. Also called second phase oil.
- the first-phase-oil and second-phase-oil are elutriated for certain time.
- the elutriated oils are then passed through 4-level filter and again elutriated for a predetermined time.
- the oils are refiltered through 4-level filter and a higher than the first 4-level filter, to obtain the final oil for use.
- the extracted oil in the first phase is superior to the ordinary oil especially in the medical effect.
- the extracted Jojoba oil has been effectively used with lidocaine in the treatment of recurrent aphthous ulceration. It has been used in toothpaste to treat gingivitis and improve the circulation of gingiva. It has been effectively used with zinc oxide in temporary filling. It has also been effectively used in the treatment of the dry socket as a side effect of chemotherapy and radiotherapy.
- the Jojoba Oil is effective in treating and reliving pains of polyarthitis, rheumatic pains, arthralgia, and spondylitis. It is effective in enhancing the effect of physiotherapy and supporting body to regain its physical ability in addition to eliminating the stress and cramps.
- Jojoba oil is used by being added to other medicines, for achieving better effects of the novel medicine without any side effects. Examples are as following:
- Vaginal suppository containing 20% of Jojoba oil by weight can be used in treating non-infective vaginitis.
- Jojoba oil is extracted by pressing the crashed seeds gradually under pressure form 1 to 35-38 Ton/Inch to obtain first phase oil, then meal well be crashed again and pressed under pressure up to 100 Ton/Inch to obtain second phase oil, then each type of oil will go through different levels of filtration, since the first phase oil is used for medical application for treating many illnesses.
- Jojoba oil and its derivatives are extracted including straight chains of mono-ethylenic acids and mono ethylenic alcohols; further more Jojoba oil is non-volatile, not subject to oxidation and not liable to rancidity in addition to its high penetrability to skin as a result of its low viscosity, high unsaturation, low saponification number, short carbon chain length, low lecithin, straight chain molecule and branched esters.
- the Jojoba oil is used as anti-bacteria, skin protective, anti-allergic, anti-inflammatory, anti-fungal, improving wound healing and blood circulation in the skin.
- Jojoba oil as an essential element, is used for treating many dermal diseases.
- Jojoba oil is used as an essential element, in the treatment of the inflammation of mucus membrane of the mouth, temporary filling and dry sockets.
- Jojoba oil is used as a main element in treating and reliving pains of polyarthitis, rheumatic pains, arthralgia, and spondylitis.
- Jojoba oil is used as a main element, for treating otitis externa and otitis media.
- Jojoba oil is used in treatment of thrombosis.
- Jojoba oil is used in treatment of some general surgeries such as anal fissure, anal fistula, prostatits, and Hiemorroids (at 2 nd degree).
- Jojoba oil is used as a main element in treatment of vaginitis, and nipple crakes in addition to reliving the pain accompanied with dysmenorrhoea.
- compound contain 10% of Jojoba oil by weight and 0.5% of lidocaine hydrochloride by weight, is particularly effective in treating mouth ulcer and gingivostomatitis and removing the erythena in addition to reducing Edema associated to these inflammations—this effect returns to the Jojoba oil properties as anti-bacterial and anti-inflammation substance.
- the Jojoba oil acts as a painkiller for the conditions.
- Some of the Jojoba oil's indications are: gingivostomatitis and conditions resulted from using antibiotics for long time. Moreover, this compound has no side effects.
- preparation contains 50% of Jojoba oil by weight and 2% of salicylic acid by weight and is used for treating acne, psoriasis dandruff sebum (abnormal) excessive exudatation of seba ceous glands in skin and fish skin disease; it could also be used in treatment of fungal infection as tinia (tinea). This preparation also has no side effect.
- a suppository containing 20% jojoba oil by weight can be used to treat the anal fissure. It could relieve the intensity of pains and the complications in many patients as well as eliminating pills. Moreover, this suppository has no side effects.
- vaginal suppository containing 20% Jojoba oil by weight is used to eliminate the vaginitis (acute or recurrent). This suppository has no side effects.
Abstract
In accordance with the present invention Jojoba Oil may be used in accordance with the treatment of and preventative measures associated with Gynecology of Obstetrics and general surgery, as well as in the treatment of eye diseases, inflammation of the internal, middle or external ear, rheumatic pain and arthritis, gingivostomatitis, toothache and dermal diseases. Jojoba oil is a natural product and is characterized by being non-irritant and non-allergic to skin and mucous membrane. This oil has lubricant, moisturizing and soothing properties, as well as having anti-bacterial, anti-inflammatory and anti-oxidant properties. It has a very high healing power and improves blood circulation, and also has high penetration into stratum corneum.
Description
- This application is a divisional application of U.S. patent application Ser. No. 10/189,888 and filed on Aug. 3, 2002, which claims foreign priority to Egyptian Patent Application No. 750 and filed on Jul. 7, 2001.
- The present invention relates to various medical effects of the Jojoba oil.
- Jojoba oil is used in Lubricating motors and added to some cosmetic preparations. However, such previous uses of Jojoba Oil are not related to the new uses subjected to this invention.
- In accordance with the present invention Jojoba Oil may be used in accordance with the treatment of and preventative measures associated with Gynecology of Obstetrics and general surgery, as well as in the treatment of eye diseases, inflammation of the internal, middle or external ear, rheumatic pain and arthritis, gingivostomatitis, toothache and dermal diseases.
- Moreover, the Jojoba Oil is preferably extruded in accordance with the present invention.
- Numerous other advantages and features of the invention will become readily apparent from the following detailed description of the invention and the embodiments thereof, from the claims, and from the accompanying drawings.
- While the invention is susceptible to embodiments in many different forms, there are shown in the drawings and will be described herein, in detail, the preferred embodiments of the present invention. It should be understood, however, that the present disclosure is to be considered an exemplification of the principles of the invention and is not intended to limit the spirit or scope of the invention and/or claims of the embodiments illustrated.
- Natural Jojoba oil is extracted from seeds of Jojoba shrub {Simmondsia Chinensis (LINK) Schnieder}. It is made up of straight chain esters of mono-unsaturated long chain fatty acids and fatty alcohols and has an average total carbon chain length of 42 carbons, so it is classified chemically as a liquid wax.
- Jojoba oil is composed entirely of esters of high molecular weight, straight chain mono-ethylenic acids and mono-ethylenic alcohols. The unsaturated acids are mixture of eicosanoic (C20) and docosanoic (C22), with small quantities of palmiloleic (C18) and oleic (C16) acids. The unsaturated alcohols are a mixture of eicosanol and docosanol, with smaller quantities of hexacosanol and alcohols of lower molecular weight.
- Jojoba oil is non-volatile and free from rancidity, and this is attributed in part to presence of tocopherols (natural anti-oxidant) as a minor constituent and mainly to its wax structure (It has only one alcohol group, so it is not subject to oxidation and will never become rancid). Furthermore, researches showed that Jojoba oil possesses the six general factors which increase permeation into stratum cornium:—low viscosity, high unsaturation, low saponification number, short carbon chain length, low lecithin (Jojoba oil has no lecithin), straight chain molecule and branched esters.
- Jojoba oil helps to avoid the two important causes of premature aging of the skin:—dryness and lipid perioxidation. It serves as an excellent non-occlusive moisturizing agent that enhances the flexibility and suppleness of the skin. At the same time, its exceptional non-tacky spread and lubricity leave a rich velvety after-feel.
- Jojoba oil is characterized by having 50% of its content as insaponifiables (Triterpene alcohols and Phytosterols) while other vegetable oil contain only 2-3%. Moreover applying insaponifiables to skin increases elastin formation, which in turn increases skin luster, elasticity and integration. Jojoba Oil also provides skin protection as it has anti-allergic properties, disinfectant, and produces cell stimulation, skin regeneration and stops inflammation. The pH of Jojoba oil is balanced and reveals beneficial effects for dry and damaged skin.
- Jojoba oil is also proven to have anti-inflammatory and anti-microbial effects as well. Five of the most common bacteria including staphylococcus aureus and pseudomonas aeruginosa as well as fungus candida albicans are not able to grow in Jojoba oil.
- One novel way to extract the Jojoba Oil from the Jojoba seeds is as follows. First, it has been determined that the Jojoba seeds contain 50-55% of its weight oil. The Jojoba oil is extracted in phase one by pressing the Jojoba seeds under pressure reaching gradually from 1 to 35-38 Ton/Inch. About 26-28% oil from the seeds weight is obtained form the first pressing phase, also called phase one oil, which may be used for medical application. After separating the phase-one oil from the crashed seeds, the residual squeezed seeds are pressed again under pressure up to 100 Ton/Inch, which extracts second phase oil, which may be used in cosmetic and other fields. Also called second phase oil. Independently, the first-phase-oil and second-phase-oil are elutriated for certain time. The elutriated oils are then passed through 4-level filter and again elutriated for a predetermined time. The oils are refiltered through 4-level filter and a higher than the first 4-level filter, to obtain the final oil for use. The extracted oil in the first phase is superior to the ordinary oil especially in the medical effect.
- The extracted Jojoba oil is effectively used in the treatment of the following:
- Dermal Diseases:
- It has been effectively used with salicylic acid in the treatment of psoriasis, dandruff, acne and fish skin disease. It has been effectively used with zinc oxide in the treatment of napkin dermatitis, skin rash, allergic dermatitis and monilial infection. It has been effectively used with the treatment of insect bites and the treatment of fungal infect in toes. It is effective in protecting skin from non-infective allergic materials such as liquid washing soap. It has been effectively used in treatment of mange, treating first degree burns and sun burns as well as protecting skin from hazards of ultra violate rays during sun-tanning. It is also elective as a first aid for wounds and treating inflammatory wounds and enhancing healing by primary intention. It is effective in the treatment of bedsores. It has been used in assisting treatment of alopecia areata and rogenetica. It has been used to eliminate hair lice. It has been effectively used in treatment of Herpes simplex labialis (cold sores). It has also been effectively used in healing diabetic wounds especially diabetic foot.
- Treatment of Gingivostomatitis and Toothache:
- The extracted Jojoba oil has been effectively used with lidocaine in the treatment of recurrent aphthous ulceration. It has been used in toothpaste to treat gingivitis and improve the circulation of gingiva. It has been effectively used with zinc oxide in temporary filling. It has also been effectively used in the treatment of the dry socket as a side effect of chemotherapy and radiotherapy.
- Rheumatic Pain and Arthritis:
- The Jojoba Oil is effective in treating and reliving pains of polyarthitis, rheumatic pains, arthralgia, and spondylitis. It is effective in enhancing the effect of physiotherapy and supporting body to regain its physical ability in addition to eliminating the stress and cramps.
- Inflammation of the Ear
- It has been effective in treatment of otitis externa and otitis media.
- Treatment of Eye Diseases:
- It has been effectively used in treatment of thrombosis.
- General Surgery:
- It has been effectively used as suppositories in treatment of acute and chronic anal fissure and anal fistula, as well as the treatment of prostatits, Hiemorroids (at 2nd degree) and early stages of Varicose Vein.
- Gynecology of Obstetrics:
- It has been effectively used as a Vaginal suppository in treatment of vaginitis, used in reliving the pain accompanied with dysmenorrhoea, and used in the treatment of nipple crakes and improve its healing.
- The Method of Use
- The Jojoba oil is used by being added to other medicines, for achieving better effects of the novel medicine without any side effects. Examples are as following:
- 1—10% of Jojoba oil by weight, and 0.5% of Lidocaine hydrochloride by weight are used for treating the inflammation of mucous membrane of mouth and condition resulted form administration of antibiotics for long time.
- 2—50% of Jojoba Oil by weight, and 2% salicylic acid by weight are used in ointment form for treating acne, psoriases, dandruff, sebum (abnormal excessive exudatation of sebaceous glands in skin) and fish skin disease (Thick epidermis being tough and continually scalling)
- 3—50% of Jojoba oil by weight with 8% of zinc oxide weight can be used in treating conditions of skin rash and allergic dermatitis.
- 4—As suppository contain, 20% of Jojoba oil by weight can be used to treat the anal fissure.
- 5—Vaginal suppository containing 20% of Jojoba oil by weight can be used in treating non-infective vaginitis.
- Jojoba oil is extracted by pressing the crashed seeds gradually under pressure form 1 to 35-38 Ton/Inch to obtain first phase oil, then meal well be crashed again and pressed under pressure up to 100 Ton/Inch to obtain second phase oil, then each type of oil will go through different levels of filtration, since the first phase oil is used for medical application for treating many illnesses.
- As mentioned previously, from seeds, Jojoba oil and its derivatives are extracted including straight chains of mono-ethylenic acids and mono ethylenic alcohols; further more Jojoba oil is non-volatile, not subject to oxidation and not liable to rancidity in addition to its high penetrability to skin as a result of its low viscosity, high unsaturation, low saponification number, short carbon chain length, low lecithin, straight chain molecule and branched esters.
- As motioned previously, the Jojoba oil is used as anti-bacteria, skin protective, anti-allergic, anti-inflammatory, anti-fungal, improving wound healing and blood circulation in the skin.
- As mentioned previously, Jojoba oil as an essential element, is used for treating many dermal diseases.
- As mentioned previously, Jojoba oil is used as an essential element, in the treatment of the inflammation of mucus membrane of the mouth, temporary filling and dry sockets.
- As mentioned previously, Jojoba oil is used as a main element in treating and reliving pains of polyarthitis, rheumatic pains, arthralgia, and spondylitis.
- As mentioned previously, Jojoba oil is used as a main element, for treating otitis externa and otitis media.
- As mentioned previously, as a main element, Jojoba oil is used in treatment of thrombosis.
- As mentioned previously, as a main element, Jojoba oil is used in treatment of some general surgeries such as anal fissure, anal fistula, prostatits, and Hiemorroids (at 2nd degree).
- As mentioned previously, Jojoba oil is used as a main element in treatment of vaginitis, and nipple crakes in addition to reliving the pain accompanied with dysmenorrhoea.
- As mentioned previously, compound contain 10% of Jojoba oil by weight and 0.5% of lidocaine hydrochloride by weight, is particularly effective in treating mouth ulcer and gingivostomatitis and removing the erythena in addition to reducing Edema associated to these inflammations—this effect returns to the Jojoba oil properties as anti-bacterial and anti-inflammation substance. Also, the Jojoba oil acts as a painkiller for the conditions. Some of the Jojoba oil's indications are: gingivostomatitis and conditions resulted from using antibiotics for long time. Moreover, this compound has no side effects.
- As mentioned previously, preparation contains 50% of Jojoba oil by weight and 2% of salicylic acid by weight and is used for treating acne, psoriasis dandruff sebum (abnormal) excessive exudatation of seba ceous glands in skin and fish skin disease; it could also be used in treatment of fungal infection as tinia (tinea). This preparation also has no side effect.
- As mentioned previously, a suppository containing 20% jojoba oil by weight can be used to treat the anal fissure. It could relieve the intensity of pains and the complications in many patients as well as eliminating pills. Moreover, this suppository has no side effects.
- As mentioned previously, ointments containing 50% of Jojoba oil by weight with 8% of zinc oxide by weight used in treating condition of rash, napkin dermatitis, skin inflammation, insect bytes, monilyases, and nipple fissure, no side effects have been resulted from this preparation.
- As mentioned previously, a vaginal suppository containing 20% Jojoba oil by weight is used to eliminate the vaginitis (acute or recurrent). This suppository has no side effects.
- Form all the above mentioned benefits, it becomes clear that Jojoba oil, in its all forms and cases, all the illnesses treated with it, has not any side-effects on the human body or environment.
- From the foregoing and as mentioned above, it will be observed that numerous variations and modifications may be effected without departing from the spirit and scope of the novel concept of the invention. It is to be understood that no limitation with respect to the specific methods and apparatus illustrated herein is intended or should be inferred. It is, of course, intended to cover by the appended claims all such modifications as fall within the scope of the claims.
Claims (4)
17. (Currently Amended) A method of treating skin diseases, by applying a composition that includes Jojoba oil extruded from Jojoba seeds wherein the extraction of Jojoba oil is prepared by:
pressing a Jojoba seed under pressure from approximately 1 to approximately 38 tons/inch to obtain a first phase oil,
elutriating said first phase oil for a predetermined amount of time,
filtering said elutriated oil with at least a level four filter creating a filtered oil,
re-elutriating said filtered oil for a predetermined amount of time creating a re-elutriated oil, and
re-filtering said re-elutriated oil through a at least a level 4 filter.
23. The method of claim 17 , wherein the skin diseases include but are not limited to acne, psoriasis, dandruff, fishskin disease or Ichthyosis, sebum or excessive exudation of sebaceous glands, tinea, napkin dermatitis or diaper disease, skin rash, allergic dermatitis or skin inflammation, inset bites, monilial and nipple fissure or natural crevices.
28. The method of claim 27, wherein the composition includes approximately 50% Jojoba Oil by weight and approximately 8% Zinc Oxide by weight.
25. A method of treating skin diseases, such as but not limited to acne, psoriasis, dandruff, fishskin disease or Ichthyosis, sebum or excessive exudation of sebaceous glands, and tinea by topically applying to the affected area on the human body an effective amount of a composition comprising at least Jojoba Oil and Salicylic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/792,632 US20040170712A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba Oil in the treatment of skin diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EG750 | 2001-07-07 | ||
EG20010750 | 2001-07-07 | ||
US10/189,888 US6846499B2 (en) | 2001-07-07 | 2002-07-03 | Medical effect of jojoba oil |
US10/792,632 US20040170712A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba Oil in the treatment of skin diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/189,888 Division US6846499B2 (en) | 2001-07-07 | 2002-07-03 | Medical effect of jojoba oil |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040170712A1 true US20040170712A1 (en) | 2004-09-02 |
Family
ID=8163780
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/189,888 Expired - Fee Related US6846499B2 (en) | 2001-07-07 | 2002-07-03 | Medical effect of jojoba oil |
US10/792,632 Abandoned US20040170712A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba Oil in the treatment of skin diseases |
US10/792,610 Abandoned US20040170710A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba oil in the treatment of vaginal diseases |
US10/792,611 Abandoned US20040170711A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba oil in the treatment of anal diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/189,888 Expired - Fee Related US6846499B2 (en) | 2001-07-07 | 2002-07-03 | Medical effect of jojoba oil |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/792,610 Abandoned US20040170710A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba oil in the treatment of vaginal diseases |
US10/792,611 Abandoned US20040170711A1 (en) | 2001-07-07 | 2004-03-04 | Medical effect of Jojoba oil in the treatment of anal diseases |
Country Status (6)
Country | Link |
---|---|
US (4) | US6846499B2 (en) |
EP (1) | EP1281401A3 (en) |
JP (1) | JP2003063978A (en) |
CN (1) | CN1275606C (en) |
MA (1) | MA25696A1 (en) |
TN (1) | TNSN02063A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009563A1 (en) * | 2002-07-08 | 2004-01-15 | Teunis Dekker | Method of producing vertebrate host mimic with modified lipid based media |
US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7927614B2 (en) | 2006-02-03 | 2011-04-19 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
WO2013080205A1 (en) * | 2011-11-30 | 2013-06-06 | Ibr - Israeli Biotechnology Research Ltd. | Jojoba extract useful in improving skin barrier functions |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US20150110888A1 (en) * | 2012-04-23 | 2015-04-23 | Aboca S.P.A. Societa Agricola | Compositions for the treatment of chronic ulcers |
US9427397B2 (en) | 2009-01-23 | 2016-08-30 | Obagi Medical Products, Inc. | Rosacea treatments and kits for performing them |
US9516239B2 (en) | 2012-07-26 | 2016-12-06 | DePuy Synthes Products, Inc. | YCBCR pulsed illumination scheme in a light deficient environment |
US9641815B2 (en) | 2013-03-15 | 2017-05-02 | DePuy Synthes Products, Inc. | Super resolution and color motion artifact correction in a pulsed color imaging system |
US9777913B2 (en) | 2013-03-15 | 2017-10-03 | DePuy Synthes Products, Inc. | Controlling the integral light energy of a laser pulse |
US10075626B2 (en) | 2012-07-26 | 2018-09-11 | DePuy Synthes Products, Inc. | Camera system with minimal area monolithic CMOS image sensor |
US10084944B2 (en) | 2014-03-21 | 2018-09-25 | DePuy Synthes Products, Inc. | Card edge connector for an imaging sensor |
US10251530B2 (en) | 2013-03-15 | 2019-04-09 | DePuy Synthes Products, Inc. | Scope sensing in a light controlled environment |
US10517471B2 (en) | 2011-05-12 | 2019-12-31 | DePuy Synthes Products, Inc. | Pixel array area optimization using stacking scheme for hybrid image sensor with minimal vertical interconnects |
US10568496B2 (en) | 2012-07-26 | 2020-02-25 | DePuy Synthes Products, Inc. | Continuous video in a light deficient environment |
US10881272B2 (en) | 2013-03-15 | 2021-01-05 | DePuy Synthes Products, Inc. | Minimize image sensor I/O and conductor counts in endoscope applications |
US10980406B2 (en) | 2013-03-15 | 2021-04-20 | DePuy Synthes Products, Inc. | Image sensor synchronization without input clock and data transmission clock |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138134B2 (en) * | 2001-12-18 | 2006-11-21 | Arizona Health Consulting Group, Llc | Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels |
US7025957B2 (en) * | 2002-09-06 | 2006-04-11 | Desert Whale Jojoba Company | Composition and method to whiten skin |
WO2004023979A2 (en) * | 2002-09-12 | 2004-03-25 | Biosyn, Inc. | Mucus formulation for mucosal surfaces and uses thereof |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
FR2856304B1 (en) * | 2003-06-20 | 2006-03-03 | Natural Product Consulting | COMPOSITION FOR THE PREVENTION OF INFECTIONS OF THE URINARY SYSTEM |
US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
US8455016B2 (en) * | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
CA2559503A1 (en) * | 2004-03-12 | 2006-01-12 | Melbj Holdings, Llc | Lubricant for the ocular surface |
JP2007238488A (en) * | 2006-03-07 | 2007-09-20 | Kose Corp | Emulsion type skin care preparation |
US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
JP2010522757A (en) * | 2007-03-29 | 2010-07-08 | インターナショナル フローラ テクノロジーズ,リミテッド | Treatment of mammalian skin with skin emollient fungicide |
JP4891207B2 (en) * | 2007-11-27 | 2012-03-07 | 大洋香料株式会社 | Antibacterial agent and topical skin preparation containing the same |
FR2940125B1 (en) | 2008-12-23 | 2013-03-22 | Isp Investments Inc | COSMETIC OR PHARMACEUTICAL SOOTHING COMPOSITION COMPRISING AN ACTIVATOR PEPTIDE OF HMG-COA REDUCTASE |
FR2940291B1 (en) | 2008-12-23 | 2012-12-21 | Isp Investments Inc | PEPTIDE DERIVED FROM HMG-COA REDUCTASE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
FR2944526B1 (en) | 2009-04-15 | 2013-05-10 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE HYDROLYZATE CAPABLE OF STRENGTHENING BARRIER FUNCTION |
US8933036B2 (en) | 2009-04-15 | 2015-01-13 | Isp Investments Inc. | Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair |
FR2944445B1 (en) | 2009-04-15 | 2013-08-16 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A SOOTHING PEPTIDE HYDROLYZATE |
FR2944446B1 (en) * | 2009-04-15 | 2013-08-16 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A SOOTHING PEPTIDE HYDROLYZATE |
US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
JP5747391B2 (en) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | Improved methods and compositions for safe and effective treatment of erythema |
AR076729A1 (en) | 2010-06-01 | 2011-07-06 | Univ Nac De Cordoba | PROCEDURE FOR THE OBTAINING OF A WATERPROOF DISPERSION OF ALCOHOLS AND ACIDS FROM JOJOBA OIL, PROCEDURES FOR OBTAINING OF SELF-EMPLOYED JOJOBA OIL, WATER DISPERSIONS AND EMULSIONS OF COSMETIC JUSTICE OR COSMETICS |
EP2629757A2 (en) | 2010-10-21 | 2013-08-28 | Galderma S.A. | Brimonidine gel compositions and methods of use |
JP6121561B2 (en) | 2012-12-12 | 2017-04-26 | オービス ヘルス ソリューションズ エルエルシー | Compositions and methods for tissue regeneration |
WO2021013315A1 (en) * | 2019-07-22 | 2021-01-28 | Mostafa Mariam Mohamed Kamel | Ointment for diabetic foot ulcer treatment |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4381296A (en) * | 1980-06-23 | 1983-04-26 | Tinnell James E | Treatment for herpes virus |
US4512978A (en) * | 1980-01-24 | 1985-04-23 | Inwood Louis R | Dermatological composition useful in the treatment of psoriasis |
US4585656A (en) * | 1984-08-20 | 1986-04-29 | Rosenthal Harold R | Treatment of herpes |
US5179086A (en) * | 1988-10-31 | 1993-01-12 | Wolfgang Weck | Topical ointment |
US5962441A (en) * | 1991-11-25 | 1999-10-05 | Richardson-Vicks Inc. | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
US20010001666A1 (en) * | 1999-02-11 | 2001-05-24 | Marie Harbeck | Liquid skin treatment |
US20010005509A1 (en) * | 1999-02-11 | 2001-06-28 | Marie Harbeck | Foot cream composition |
US20010014316A1 (en) * | 1999-02-11 | 2001-08-16 | Marie Harbeck | Liquid cleansing composition |
US6558710B1 (en) * | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4591602A (en) * | 1982-04-16 | 1986-05-27 | James H. Brown | Ozonide esters and topical compositions containing same |
JPS59225111A (en) * | 1983-06-07 | 1984-12-18 | Kao Corp | Composition for cleaning and wiping skin around anus |
JPS59227815A (en) * | 1983-06-08 | 1984-12-21 | Kao Corp | Skin cleaning and wiping agent composition |
US4759798A (en) * | 1983-10-19 | 1988-07-26 | Nostitz F Von | Process for the preparation of dental-technical, dental-medical and medical molding and lining materials |
DE3811081A1 (en) * | 1988-03-30 | 1989-10-12 | Schering Ag | USE OF TOPIC APPLICABLE PREPARATIONS FOR THE TREATMENT OF AGING SKIN |
JPH0816051B2 (en) * | 1988-12-07 | 1996-02-21 | エスエス製薬株式会社 | Sustained release suppositories |
JPH04346928A (en) * | 1991-05-24 | 1992-12-02 | Doujin Iyaku Kako Kk | Suppository |
US5516923A (en) * | 1992-04-27 | 1996-05-14 | Agritech International | Extracting oil from oil bearing plant parts |
EP0648114B1 (en) * | 1992-07-08 | 1997-09-17 | DIANORM G. Maierhofer GmbH | Liposomes, method of preparing them and their use in the preparation of drugs |
JP3496967B2 (en) * | 1993-12-28 | 2004-02-16 | 御木本製薬株式会社 | Antiplasmin agent |
FR2714831B1 (en) * | 1994-01-10 | 1996-02-02 | Oreal | Cosmetic and / or dermatological composition containing salicylic acid derivatives and method for solubilizing these derivatives. |
JPH0892027A (en) * | 1994-09-20 | 1996-04-09 | Shiseido Co Ltd | Solid powdery external preparation for pimple |
US6365131B1 (en) * | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
US5981499A (en) * | 1998-02-20 | 1999-11-09 | Atlantic Biomed Corporation | Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
DE19939836A1 (en) * | 1999-08-21 | 2001-02-22 | Beiersdorf Ag | Hydrous cosmetic or pharmaceutical pens |
US20010046526A1 (en) * | 2000-04-19 | 2001-11-29 | C-Quest | Treatment of fungal infections |
US6582736B2 (en) * | 2001-03-23 | 2003-06-24 | Terra De Sol | Therapeutic oil composition |
US20020187165A1 (en) * | 2001-05-15 | 2002-12-12 | Joseph F. Long | Composition for female sexual arousal |
US6893648B2 (en) * | 2002-01-04 | 2005-05-17 | Harold Mermelstein | Composition and method for treatment of vaginal dryness |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
-
2002
- 2002-06-28 TN TNTNSN02063A patent/TNSN02063A1/en unknown
- 2002-06-29 EP EP02014495A patent/EP1281401A3/en not_active Withdrawn
- 2002-07-03 US US10/189,888 patent/US6846499B2/en not_active Expired - Fee Related
- 2002-07-04 MA MA26720A patent/MA25696A1/en unknown
- 2002-07-05 CN CNB021412995A patent/CN1275606C/en not_active Expired - Fee Related
- 2002-07-05 JP JP2002198017A patent/JP2003063978A/en active Pending
-
2004
- 2004-03-04 US US10/792,632 patent/US20040170712A1/en not_active Abandoned
- 2004-03-04 US US10/792,610 patent/US20040170710A1/en not_active Abandoned
- 2004-03-04 US US10/792,611 patent/US20040170711A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4512978A (en) * | 1980-01-24 | 1985-04-23 | Inwood Louis R | Dermatological composition useful in the treatment of psoriasis |
US4381296A (en) * | 1980-06-23 | 1983-04-26 | Tinnell James E | Treatment for herpes virus |
US4585656A (en) * | 1984-08-20 | 1986-04-29 | Rosenthal Harold R | Treatment of herpes |
US5179086A (en) * | 1988-10-31 | 1993-01-12 | Wolfgang Weck | Topical ointment |
US5962441A (en) * | 1991-11-25 | 1999-10-05 | Richardson-Vicks Inc. | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
US20010001666A1 (en) * | 1999-02-11 | 2001-05-24 | Marie Harbeck | Liquid skin treatment |
US20010005509A1 (en) * | 1999-02-11 | 2001-06-28 | Marie Harbeck | Foot cream composition |
US20010014316A1 (en) * | 1999-02-11 | 2001-08-16 | Marie Harbeck | Liquid cleansing composition |
US6558710B1 (en) * | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009563A1 (en) * | 2002-07-08 | 2004-01-15 | Teunis Dekker | Method of producing vertebrate host mimic with modified lipid based media |
US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7927614B2 (en) | 2006-02-03 | 2011-04-19 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
US8148563B2 (en) | 2006-02-03 | 2012-04-03 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
US8505730B2 (en) | 2008-01-04 | 2013-08-13 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
US9427397B2 (en) | 2009-01-23 | 2016-08-30 | Obagi Medical Products, Inc. | Rosacea treatments and kits for performing them |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US11026565B2 (en) | 2011-05-12 | 2021-06-08 | DePuy Synthes Products, Inc. | Image sensor for endoscopic use |
US10709319B2 (en) | 2011-05-12 | 2020-07-14 | DePuy Synthes Products, Inc. | System and method for sub-column parallel digitizers for hybrid stacked image sensor using vertical interconnects |
US10517471B2 (en) | 2011-05-12 | 2019-12-31 | DePuy Synthes Products, Inc. | Pixel array area optimization using stacking scheme for hybrid image sensor with minimal vertical interconnects |
US10537234B2 (en) | 2011-05-12 | 2020-01-21 | DePuy Synthes Products, Inc. | Image sensor with tolerance optimizing interconnects |
US11848337B2 (en) | 2011-05-12 | 2023-12-19 | DePuy Synthes Products, Inc. | Image sensor |
US11682682B2 (en) | 2011-05-12 | 2023-06-20 | DePuy Synthes Products, Inc. | Pixel array area optimization using stacking scheme for hybrid image sensor with minimal vertical interconnects |
US11432715B2 (en) | 2011-05-12 | 2022-09-06 | DePuy Synthes Products, Inc. | System and method for sub-column parallel digitizers for hybrid stacked image sensor using vertical interconnects |
US11179029B2 (en) | 2011-05-12 | 2021-11-23 | DePuy Synthes Products, Inc. | Image sensor with tolerance optimizing interconnects |
US10863894B2 (en) | 2011-05-12 | 2020-12-15 | DePuy Synthes Products, Inc. | System and method for sub-column parallel digitizers for hybrid stacked image sensor using vertical interconnects |
US11109750B2 (en) | 2011-05-12 | 2021-09-07 | DePuy Synthes Products, Inc. | Pixel array area optimization using stacking scheme for hybrid image sensor with minimal vertical interconnects |
CN105708870A (en) * | 2011-11-30 | 2016-06-29 | Ibr以色列生物科技研究有限公司 | Jojoba extract useful in improving skin barrier functions |
US9949918B2 (en) | 2011-11-30 | 2018-04-24 | IBR—Israeli Biotechnology Research Ltd. | Jojoba extract useful in improving skin barrier functions |
CN103957884A (en) * | 2011-11-30 | 2014-07-30 | Ibr以色列生物科技研究有限公司 | Jojoba extract useful in improving skin barrier functions |
WO2013080205A1 (en) * | 2011-11-30 | 2013-06-06 | Ibr - Israeli Biotechnology Research Ltd. | Jojoba extract useful in improving skin barrier functions |
US10953066B2 (en) * | 2012-04-23 | 2021-03-23 | Aboca S.P.A. Società Agricola | Compositions for the treatment of chronic ulcers |
US20150110888A1 (en) * | 2012-04-23 | 2015-04-23 | Aboca S.P.A. Societa Agricola | Compositions for the treatment of chronic ulcers |
US10568496B2 (en) | 2012-07-26 | 2020-02-25 | DePuy Synthes Products, Inc. | Continuous video in a light deficient environment |
US11070779B2 (en) | 2012-07-26 | 2021-07-20 | DePuy Synthes Products, Inc. | YCBCR pulsed illumination scheme in a light deficient environment |
US10701254B2 (en) | 2012-07-26 | 2020-06-30 | DePuy Synthes Products, Inc. | Camera system with minimal area monolithic CMOS image sensor |
US10277875B2 (en) | 2012-07-26 | 2019-04-30 | DePuy Synthes Products, Inc. | YCBCR pulsed illumination scheme in a light deficient environment |
US10785461B2 (en) | 2012-07-26 | 2020-09-22 | DePuy Synthes Products, Inc. | YCbCr pulsed illumination scheme in a light deficient environment |
US11863878B2 (en) | 2012-07-26 | 2024-01-02 | DePuy Synthes Products, Inc. | YCBCR pulsed illumination scheme in a light deficient environment |
US9516239B2 (en) | 2012-07-26 | 2016-12-06 | DePuy Synthes Products, Inc. | YCBCR pulsed illumination scheme in a light deficient environment |
US11766175B2 (en) | 2012-07-26 | 2023-09-26 | DePuy Synthes Products, Inc. | Camera system with minimal area monolithic CMOS image sensor |
US9762879B2 (en) | 2012-07-26 | 2017-09-12 | DePuy Synthes Products, Inc. | YCbCr pulsed illumination scheme in a light deficient environment |
US10075626B2 (en) | 2012-07-26 | 2018-09-11 | DePuy Synthes Products, Inc. | Camera system with minimal area monolithic CMOS image sensor |
US11083367B2 (en) | 2012-07-26 | 2021-08-10 | DePuy Synthes Products, Inc. | Continuous video in a light deficient environment |
US11089192B2 (en) | 2012-07-26 | 2021-08-10 | DePuy Synthes Products, Inc. | Camera system with minimal area monolithic CMOS image sensor |
US11344189B2 (en) | 2013-03-15 | 2022-05-31 | DePuy Synthes Products, Inc. | Image sensor synchronization without input clock and data transmission clock |
US10670248B2 (en) | 2013-03-15 | 2020-06-02 | DePuy Synthes Products, Inc. | Controlling the integral light energy of a laser pulse |
US10980406B2 (en) | 2013-03-15 | 2021-04-20 | DePuy Synthes Products, Inc. | Image sensor synchronization without input clock and data transmission clock |
US10205877B2 (en) | 2013-03-15 | 2019-02-12 | DePuy Synthes Products, Inc. | Super resolution and color motion artifact correction in a pulsed color imaging system |
US9777913B2 (en) | 2013-03-15 | 2017-10-03 | DePuy Synthes Products, Inc. | Controlling the integral light energy of a laser pulse |
US11185213B2 (en) | 2013-03-15 | 2021-11-30 | DePuy Synthes Products, Inc. | Scope sensing in a light controlled environment |
US11253139B2 (en) | 2013-03-15 | 2022-02-22 | DePuy Synthes Products, Inc. | Minimize image sensor I/O and conductor counts in endoscope applications |
US11903564B2 (en) | 2013-03-15 | 2024-02-20 | DePuy Synthes Products, Inc. | Image sensor synchronization without input clock and data transmission clock |
US10917562B2 (en) | 2013-03-15 | 2021-02-09 | DePuy Synthes Products, Inc. | Super resolution and color motion artifact correction in a pulsed color imaging system |
US10251530B2 (en) | 2013-03-15 | 2019-04-09 | DePuy Synthes Products, Inc. | Scope sensing in a light controlled environment |
US11674677B2 (en) | 2013-03-15 | 2023-06-13 | DePuy Synthes Products, Inc. | Controlling the integral light energy of a laser pulse |
US9641815B2 (en) | 2013-03-15 | 2017-05-02 | DePuy Synthes Products, Inc. | Super resolution and color motion artifact correction in a pulsed color imaging system |
US10881272B2 (en) | 2013-03-15 | 2021-01-05 | DePuy Synthes Products, Inc. | Minimize image sensor I/O and conductor counts in endoscope applications |
US10911649B2 (en) | 2014-03-21 | 2021-02-02 | DePuy Synthes Products, Inc. | Card edge connector for an imaging sensor |
US11438490B2 (en) | 2014-03-21 | 2022-09-06 | DePuy Synthes Products, Inc. | Card edge connector for an imaging sensor |
US10084944B2 (en) | 2014-03-21 | 2018-09-25 | DePuy Synthes Products, Inc. | Card edge connector for an imaging sensor |
Also Published As
Publication number | Publication date |
---|---|
US20040170711A1 (en) | 2004-09-02 |
EP1281401A3 (en) | 2003-06-25 |
US6846499B2 (en) | 2005-01-25 |
MA25696A1 (en) | 2003-04-01 |
JP2003063978A (en) | 2003-03-05 |
CN1275606C (en) | 2006-09-20 |
EP1281401A2 (en) | 2003-02-05 |
US20040170710A1 (en) | 2004-09-02 |
US20030008022A1 (en) | 2003-01-09 |
TNSN02063A1 (en) | 2005-12-23 |
CN1395964A (en) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6846499B2 (en) | Medical effect of jojoba oil | |
RU2320362C2 (en) | Proanthocyanidin-containing topical pharmaceutical compositions for treatment of dermatitis | |
DE60014659T2 (en) | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SERINIAN PROTEASES FROM CODES AND THEIR PHARMACEUTICAL AND COSMETIC USES | |
AU752204B2 (en) | Substance mixture for topical application comprising olive oil and honey | |
EP2364713B1 (en) | Dermatological composition for use in the treatment of skin burns, skin diseases and infected wounds | |
US7597911B2 (en) | Method and composition for treatment of wounds and burns | |
US20020176876A1 (en) | Topical therapeutic skin care system | |
CN102283899A (en) | Traditional Chinese medicine external preparation and application thereof | |
PL223972B1 (en) | Essential oil and aloe vera for the treatment and prophylaxis of inflammation caused by grain mites, especially blepharitis, a pharmaceutical composition comprising an essential oil and/or aloe, and the use of the essential oil and aloe vera and its composition for the preparation for the treatment and prevention of these inflammatory conditions | |
US20080193552A1 (en) | Topical medicament for skin injuries and disorders | |
KR20160085231A (en) | Propionibacterium Acnes Antimicrobial and Cosmetics Therewith | |
KR100892742B1 (en) | Skin external composition for treating pimple | |
RU2695349C1 (en) | Wound healing ointment based on garden cabbage (brassica oleracea) | |
RU2128990C1 (en) | Anti-inflammatory and wound-healing ointment "vundehil" | |
Naeimifar et al. | Successful treatment of ulcers with honey-based topical preparation: five case report | |
WO2004096119A2 (en) | Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same | |
CH712470A2 (en) | Product for treating and preventing burnout syndromes of the scalp and the skin. | |
Tajarudin et al. | Prevention Of Incontinence-Associated Dermatitis Of Immobility Patients Using Aloe Verra Skin Barrier And Olive Oil | |
KR101074985B1 (en) | Cosmetic compositions for skin care containing extract of Boswellia carterii Birdw. | |
RU2195922C2 (en) | Antivaricose cream | |
WO2021236108A1 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
BG2621U1 (en) | A medicinal cream | |
DE102017002125A1 (en) | Cosmetic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |